Filter News
Area of Research
News Topics
- (-) Artificial Intelligence (1)
- (-) Biomedical (2)
- (-) Materials Science (5)
- Biology (3)
- Computer Science (2)
- Coronavirus (1)
- Cybersecurity (1)
- Decarbonization (1)
- Energy Storage (2)
- Environment (2)
- Frontier (1)
- Fusion (1)
- Materials (4)
- Nanotechnology (1)
- Neutron Science (20)
- Physics (3)
- Quantum Science (2)
- Security (1)
- Space Exploration (1)
- Transportation (1)
Media Contacts
Paul Langan will join ORNL in the spring as associate laboratory director for the Biological and Environmental Systems Science Directorate.
While studying how bio-inspired materials might inform the design of next-generation computers, scientists at ORNL achieved a first-of-its-kind result that could have big implications for both edge computing and human health.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
ASM International recently elected three researchers from ORNL as 2021 fellows. Selected were Beth Armstrong and Govindarajan Muralidharan, both from ORNL’s Material Sciences and Technology Division, and Andrew Payzant from the Neutron Scattering Division.
Scientists at ORNL and the University of Tennessee, Knoxville, have found a way to simultaneously increase the strength and ductility of an alloy by introducing tiny precipitates into its matrix and tuning their size and spacing.
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.